Oncolys BioPharma Past Earnings Performance
Past criteria checks 0/6
Oncolys BioPharma's earnings have been declining at an average annual rate of -6.8%, while the Biotechs industry saw earnings growing at 23% annually. Revenues have been declining at an average rate of 2% per year.
Key information
-6.8%
Earnings growth rate
0.5%
EPS growth rate
| Biotechs Industry Growth | 31.9% |
| Revenue growth rate | -2.0% |
| Return on equity | -131.5% |
| Net Margin | -3,075.1% |
| Next Earnings Update | 10 May 2024 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How Oncolys BioPharma makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
| Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 31 Dec 23 | 63 | -1,939 | 1,961 | 0 |
| 30 Sep 23 | 255 | -1,587 | 1,641 | 0 |
| 30 Jun 23 | 613 | -1,447 | 1,580 | 0 |
| 31 Mar 23 | 818 | -1,144 | 1,373 | 0 |
| 31 Dec 22 | 976 | -1,149 | 1,561 | 0 |
| 30 Sep 22 | 1,109 | -1,471 | 1,823 | 0 |
| 30 Jun 22 | 876 | -1,535 | 1,834 | 0 |
| 31 Mar 22 | 773 | -1,594 | 1,847 | 0 |
| 31 Dec 21 | 642 | -1,615 | 1,722 | 0 |
| 30 Sep 21 | 425 | -1,529 | 1,779 | 0 |
| 30 Jun 21 | 371 | -2,081 | 1,957 | 0 |
| 31 Mar 21 | 307 | -2,160 | 1,977 | 0 |
| 31 Dec 20 | 314 | -2,095 | 1,925 | 0 |
| 30 Sep 20 | 871 | -1,867 | 1,874 | 0 |
| 30 Jun 20 | 819 | -1,304 | 1,667 | 0 |
| 31 Mar 20 | 1,326 | -838 | 1,712 | 0 |
| 31 Dec 19 | 1,304 | -912 | 1,745 | 0 |
| 30 Sep 19 | 690 | -923 | 1,518 | 0 |
| 30 Jun 19 | 699 | -866 | 1,476 | 0 |
| 31 Mar 19 | 183 | -1,283 | 1,358 | 0 |
| 31 Dec 18 | 169 | -1,234 | 1,295 | 0 |
| 30 Sep 18 | 319 | -1,213 | 1,387 | 0 |
| 30 Jun 18 | 300 | -1,214 | 1,371 | 0 |
| 31 Mar 18 | 248 | -1,160 | 1,293 | 0 |
| 31 Dec 17 | 229 | -1,091 | 1,236 | 0 |
Quality Earnings: 4588 is currently unprofitable.
Growing Profit Margin: 4588 is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: 4588 is unprofitable, and losses have increased over the past 5 years at a rate of 6.8% per year.
Accelerating Growth: Unable to compare 4588's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: 4588 is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.9%).
Return on Equity
High ROE: 4588 has a negative Return on Equity (-131.5%), as it is currently unprofitable.